Report : A-Z NHS England items in Formulary 27/02/2021 09:37:03

[Back]

Section Status NHS England Name 20 Non Formulary 3, 4 Diaminopyridine  08.01.05 Restricted Use Abemaciclib Verzenios® 11.99.99.99 Restricted Use Adalimumab Amgevita®, Humira®, Imraldi® 13.05.03 Restricted Use Adalimumab Amgevita®,Humira®, Imraldi® 08.01.05 Restricted Use Afatinib Giotrif® 10.01.03 Restricted Use Anakinra Kineret® 09.08.01 Restricted Use Asfotase alfa Strensiq® 10.02 Restricted Use Ataluren Translarna® 08.01.05 Restricted Use Atezolizumab Tecentriq® 10.04 Restricted Use Autologous chondrocyte implantation (ACI)  08.01.05 Restricted Use Avelumab Bavencio® 05.01.09 Restricted Use Bedaquiline Sirturo® 03.04.02 Restricted Use Benralizumab Fasenra® 09.08.01 Formulary Betaine Cystadane® 05.03.01 Restricted Use Bictegravir, emtricitabine, tenofovir alafenamide  Biktarvy® 08.01.05 Restricted Use Binimetinib Mektovi® 08.02.03 Restricted Use Blinatumomab Blincyto® 08.01.05 Restricted Use Brigatinib Alunbrig® 08.01.05 Restricted Use Cabozantinib Cabometyx® 08.01.05 Restricted Use Carfilzomib Kyprolis® 08.01.05 Restricted Use Ceritinib Zykadia® 10.01.03 Restricted Use Certolizumab Pegol Cimzia® 09.08.01 Restricted Use Chenodeoxycholic acid  08.01.03 Restricted Use Cladribine Mavenclad® 08.01.05 Restricted Use Crizotinib Xalkori® 05.03.03.02 Restricted Use Daclatasvir  Daklinza® 08.01.05 Restricted Use Daratumumab Darzalex® 05.03.03.02 Restricted Use Dasabuvir Exviera® 20 Non Formulary Dibotermin alfa (recombinant human (Bone Morphogenetic Protein-2; rhBMP-2)  InductOs® 1.5 mg/ml powder, solvent and matrix for implantation matrix 20 Restricted Use Dibotermin Alfa, rhBMP-2 (Bone morphogenetic protein-2 ) Inductos® 08.02.04 Formulary Dimethyl fumarate Tecfidera® 08.02.03 Restricted Use Durvalumab Imfinzi® 09.01.03 Restricted Use Eculizumab  05.03.03.02 Restricted Use Elbasvir and Grazoprevir  Zepatier® 09.08.01 Restricted Use Eliglustat Cerdelga® 02.11 Restricted Use Emicizumab Hemlibra® 08.01.05 Restricted Use Encorafenib Braftovi® 13.05.03 Restricted Use Etanercept Enbrel®, Benepali® 06.06.01 Restricted Use Etelcalcetide Parsabiv® 08.01.05 Restricted Use Everolimus Votubia® 09.01.06 Formulary Filgrastim  05.03.03.02 Restricted Use Glecaprevir and Pibrentasvir Maviret® 09.08.01 Restricted Use Glycerol Phenylbutyrate Ravicti® 11.08 Restricted Use Holoclar®  08.01.05 Restricted Use Ibrutinib Imbruvica® 08.03.04.01 Restricted Use Intrabeam radiotherapy system Carl Zeiss UK 03.07 Restricted Use Ivacaftor  08.01.05 Restricted Use Ixazomib Ninlaro® 03.04.03 Restricted Use Lanadelumab Takhzyro® 08.01.05 Restricted Use Larotrectinib Vitrakvi® 05.03.03.02 Restricted Use Ledipasvir and Sofosbuvir Harvoni® 09.01.06 Restricted Use Lenograstim Granocyte® 08.01.05 Restricted Use Lenvatinib Lenvima® 08.01.05 Restricted Use Lenvatinib Kisplyx® 09.08.01 Formulary Levocarnitine Carnitor® 08.01.05 Restricted Use Liposomal Cytarabine–Daunorubicin  Vyxeos® 03.07 Restricted Use Lumacaftor/ivacaftor Orkambi® 03.04.02 Restricted Use Mepolizumab Nucala® 09.08.01 Formulary Mercaptamine  08.01.05 Restricted Use Midostaurin Rydapt® 08.01.05 Restricted Use Niraparib Zejula® 09.08.01 Formulary Nitisinone Orfadin® 08.02.04 Restricted Use Nivolumab Opdivo ® 10.02 Restricted Use Nusinersen Spinraza® 01.09.01 Restricted Use Obeticholic acid Ocaliva® 08.02.04 Restricted Use Ocrelizumab Ocrevus® 08.03.04.03 Restricted Use Octreotide Sandostatin® 08.03.04.03 Restricted Use Octreotide Sandostatin Lar® 05.03.03.02 Restricted Use Ombitasvir, Paritaprevir and Ritonavir Viekirax® 08.01.05 Restricted Use Paclitaxel  08.01.05 Restricted Use Palbociclib Ibrance® 09.01.06 Restricted Use Pegfilgrastim Neulasta® 08.01.05 Restricted Use Pembrolizumab Keytruda® 09.01.07 Restricted Use Plerixafor Mozobil® 05.02 Restricted Use Posaconazole (IV) Noxafil® 05.02 Restricted Use Posaconazole (oral) Noxafil® 08.01.05 Restricted Use Ribociclib Kisqali® 10.02 Restricted Use Risdiplam Evrysdi 03.03.03 Restricted Use Roflumilast Daxas® 20.01 Restricted Use Sarilumab  09.08.01 Formulary Sodium Phenylbutyrate  08.01.05 Restricted Use Streptozocin Zanosar® 03.07 Restricted Use Tezacaftor/Ivacaftor Symkevi® 08.01.05 Restricted Use Tisagenlecleucel  Kymriah® 10.01.03 Restricted Use Tocilizumab RoActemra® 20.01 Restricted Use Tocilizumab  06.05.02 Restricted Use Tolvaptan Samsca® 08.01.05 Restricted Use Trastuzumab emtansine Kadcyla®

Cambridgeshire and Peterborough